Do analysts prefer COSM or YI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cosmos Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 111 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, COSM or YI?

111 has higher revenue and earnings than Cosmos Health. 111 is trading at a lower price-to-earnings ratio than Cosmos Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cosmos Health $73.73M 0.18 -$19.15M -$0.64 N/A 111 $11.39B 0.00 -$9.65M -$1.40 N/A

Is COSM or YI more profitable?

111 has a net margin of -0.76% compared to Cosmos Health's net margin of -33.08%. 111's return on equity of 0.00% beat Cosmos Health's return on equity. Company Net Margins Return on Equity Return on Assets Cosmos Health -33.08% -56.88% -18.03% 111 -0.76% N/A -3.80%

Do analysts prefer WGRX or YI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Wellgistics Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 111 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, WGRX or YI?

111 has higher revenue and earnings than Wellgistics Health. 111 is trading at a lower price-to-earnings ratio than Wellgistics Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Wellgistics Health $23.34M 0.37 -$101.28M -$44.50 N/A 111 $11.39B 0.00 -$9.65M -$1.40 N/A

Is WGRX or YI more profitable?

111 has a net margin of -0.76% compared to Wellgistics Health's net margin of -545.69%. Company Net Margins Return on Equity Return on Assets Wellgistics Health -545.69% N/A -145.69% 111 -0.76% N/A -3.80%

Do analysts rate YI or HKPD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 111 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Hong Kong Pharma Digital Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, YI or HKPD?

Hong Kong Pharma Digital Technology has lower revenue, but higher earnings than 111. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 111 $11.39B 0.00 -$9.65M -$1.40 N/A Hong Kong Pharma Digital Technology $13.43M 0.33 -$1.14M N/A N/A

Is YI or HKPD more profitable?

Hong Kong Pharma Digital Technology has a net margin of 0.00% compared to 111's net margin of -0.76%. Company Net Margins Return on Equity Return on Assets 111 -0.76% N/A -3.80% Hong Kong Pharma Digital Technology N/A N/A N/A

Do analysts rate YI or RDGT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 111 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Ridgetech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, YI or RDGT?

Ridgetech has lower revenue, but higher earnings than 111. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 111 $11.39B 0.00 -$9.65M -$1.40 N/A Ridgetech $132.16M 0.02 -$1.25M N/A N/A

Is YI or RDGT more profitable?

Ridgetech has a net margin of 0.00% compared to 111's net margin of -0.76%. Company Net Margins Return on Equity Return on Assets 111 -0.76% N/A -3.80% Ridgetech N/A N/A N/A

Do analysts prefer MCK or YI?

McKesson currently has a consensus price target of $973.44, suggesting a potential upside of 12.89%. Given McKesson's stronger consensus rating and higher possible upside, analysts clearly believe McKesson is more favorable than 111. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score McKesson 0 Sell rating(s) 4 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 2.78 111 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, MCK or YI?

McKesson has higher revenue and earnings than 111. 111 is trading at a lower price-to-earnings ratio than McKesson, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio McKesson $410.98B 0.24 $4.76B $37.37 23.07 111 $11.39B 0.00 -$9.65M -$1.40 N/A

Is MCK or YI more profitable?

McKesson has a net margin of 1.12% compared to 111's net margin of -0.76%. 111's return on equity of 0.00% beat McKesson's return on equity. Company Net Margins Return on Equity Return on Assets McKesson 1.12% -253.21% 5.90% 111 -0.76% N/A -3.80%

111 (YI) Competitors

$3.57 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Compare

YI vs. COSM, WGRX, HKPD, RDGT, and MCK

Should you buy 111 stock or one of its competitors? 111's main competitors and comparable companies include Cosmos Health (COSM), Wellgistics Health (WGRX), Hong Kong Pharma Digital Technology (HKPD), Ridgetech (RDGT), and McKesson (MCK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare distributors" industry.

How does 111 compare to Cosmos Health?

Cosmos Health (NASDAQ:COSM) and 111 (NASDAQ:YI) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

Cosmos Health has a beta of 4.8, meaning that its share price is 380% more volatile than the broader market. Comparatively, 111 has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cosmos Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
111	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

12.6% of Cosmos Health shares are held by institutional investors. Comparatively, 21.3% of 111 shares are held by institutional investors. 26.2% of Cosmos Health shares are held by company insiders. Comparatively, 43.9% of 111 shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Cosmos Health had 14 more articles in the media than 111. MarketBeat recorded 14 mentions for Cosmos Health and 0 mentions for 111. Cosmos Health's average media sentiment score of 0.18 beat 111's score of 0.00 indicating that Cosmos Health is being referred to more favorably in the media.

Company	Overall Sentiment
Cosmos Health	Neutral
111	Neutral

111 has higher revenue and earnings than Cosmos Health. 111 is trading at a lower price-to-earnings ratio than Cosmos Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cosmos Health	$73.73M	0.18	-$19.15M	-$0.64	N/A
111	$11.39B	0.00	-$9.65M	-$1.40	N/A

111 has a net margin of -0.76% compared to Cosmos Health's net margin of -33.08%. 111's return on equity of 0.00% beat Cosmos Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cosmos Health	-33.08%	-56.88%	-18.03%
111	-0.76%	N/A	-3.80%

Summary

111 beats Cosmos Health on 7 of the 13 factors compared between the two stocks.

How does 111 compare to Wellgistics Health?

Wellgistics Health (NASDAQ:WGRX) and 111 (NASDAQ:YI) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

111 has a net margin of -0.76% compared to Wellgistics Health's net margin of -545.69%.

Company	Net Margins	Return on Equity	Return on Assets
Wellgistics Health	-545.69%	N/A	-145.69%
111	-0.76%	N/A	-3.80%

Wellgistics Health has a beta of -1.47, meaning that its stock price is 247% less volatile than the broader market. Comparatively, 111 has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Wellgistics Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
111	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

111 has higher revenue and earnings than Wellgistics Health. 111 is trading at a lower price-to-earnings ratio than Wellgistics Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Wellgistics Health	$23.34M	0.37	-$101.28M	-$44.50	N/A
111	$11.39B	0.00	-$9.65M	-$1.40	N/A

In the previous week, Wellgistics Health's average media sentiment score of 0.00 equaled 111'saverage media sentiment score.

Company	Overall Sentiment
Wellgistics Health	Neutral
111	Neutral

21.3% of 111 shares are held by institutional investors. 27.0% of Wellgistics Health shares are held by company insiders. Comparatively, 43.9% of 111 shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

111 beats Wellgistics Health on 8 of the 10 factors compared between the two stocks.

How does 111 compare to Hong Kong Pharma Digital Technology?

111 (NASDAQ:YI) and Hong Kong Pharma Digital Technology (NASDAQ:HKPD) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

In the previous week, Hong Kong Pharma Digital Technology's average media sentiment score of 0.80 beat 111's score of 0.00 indicating that Hong Kong Pharma Digital Technology is being referred to more favorably in the news media.

Company	Overall Sentiment
111	Neutral
Hong Kong Pharma Digital Technology	Positive

Hong Kong Pharma Digital Technology has lower revenue, but higher earnings than 111.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
111	$11.39B	0.00	-$9.65M	-$1.40	N/A
Hong Kong Pharma Digital Technology	$13.43M	0.33	-$1.14M	N/A	N/A

111 has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market. Comparatively, Hong Kong Pharma Digital Technology has a beta of 2.32, indicating that its stock price is 132% more volatile than the broader market.

Hong Kong Pharma Digital Technology has a net margin of 0.00% compared to 111's net margin of -0.76%.

Company	Net Margins	Return on Equity	Return on Assets
111	-0.76%	N/A	-3.80%
Hong Kong Pharma Digital Technology	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
111	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Hong Kong Pharma Digital Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

21.3% of 111 shares are held by institutional investors. 43.9% of 111 shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Hong Kong Pharma Digital Technology beats 111 on 6 of the 9 factors compared between the two stocks.

How does 111 compare to Ridgetech?

111 (NASDAQ:YI) and Ridgetech (NASDAQ:RDGT) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

Ridgetech has a net margin of 0.00% compared to 111's net margin of -0.76%.

Company	Net Margins	Return on Equity	Return on Assets
111	-0.76%	N/A	-3.80%
Ridgetech	N/A	N/A	N/A

111 has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market. Comparatively, Ridgetech has a beta of -0.13, indicating that its share price is 113% less volatile than the broader market.

21.3% of 111 shares are held by institutional investors. Comparatively, 45.3% of Ridgetech shares are held by institutional investors. 43.9% of 111 shares are held by company insiders. Comparatively, 22.6% of Ridgetech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, 111's average media sentiment score of 0.00 equaled Ridgetech'saverage media sentiment score.

Company	Overall Sentiment
111	Neutral
Ridgetech	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
111	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ridgetech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Ridgetech has lower revenue, but higher earnings than 111.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
111	$11.39B	0.00	-$9.65M	-$1.40	N/A
Ridgetech	$132.16M	0.02	-$1.25M	N/A	N/A

Summary

Ridgetech beats 111 on 5 of the 8 factors compared between the two stocks.

How does 111 compare to McKesson?

McKesson (NYSE:MCK) and 111 (NASDAQ:YI) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

85.1% of McKesson shares are owned by institutional investors. Comparatively, 21.3% of 111 shares are owned by institutional investors. 0.1% of McKesson shares are owned by company insiders. Comparatively, 43.9% of 111 shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, McKesson had 74 more articles in the media than 111. MarketBeat recorded 74 mentions for McKesson and 0 mentions for 111. McKesson's average media sentiment score of 1.60 beat 111's score of 0.00 indicating that McKesson is being referred to more favorably in the media.

Company	Overall Sentiment
McKesson	Very Positive
111	Neutral

McKesson has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market. Comparatively, 111 has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market.

McKesson has higher revenue and earnings than 111. 111 is trading at a lower price-to-earnings ratio than McKesson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
McKesson	$410.98B	0.24	$4.76B	$37.37	23.07
111	$11.39B	0.00	-$9.65M	-$1.40	N/A

McKesson has a net margin of 1.12% compared to 111's net margin of -0.76%. 111's return on equity of 0.00% beat McKesson's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
McKesson	1.12%	-253.21%	5.90%
111	-0.76%	N/A	-3.80%

McKesson currently has a consensus price target of $973.44, suggesting a potential upside of 12.89%. Given McKesson's stronger consensus rating and higher possible upside, analysts clearly believe McKesson is more favorable than 111.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
McKesson	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.78
111	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

McKesson beats 111 on 13 of the 16 factors compared between the two stocks.

Get 111 News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding YI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

YI vs. The Competition

Export

Metric	111	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$31.36M	$9.84B	$7.32B	$12.82B
Dividend Yield	N/A	2.55%	2.54%	10.78%
P/E Ratio	-2.55	34.38	272.90	24.25
Price / Sales	0.00	4.95	632.64	97.63
Price / Cash	N/A	24.64	29.03	36.90
Price / Book	-0.30	5.40	11.25	6.42
Net Income	-$9.65M	$309.96M	$3.47B	$348.89M
7 Day Performance	-1.11%	0.99%	2.33%	0.57%
1 Month Performance	-5.05%	2.30%	7.72%	4.90%
1 Year Performance	-48.34%	15.69%	25.22%	17.06%

111 Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
YI 111	0.7224 of 5 stars	$3.57 flat	N/A	-48.3%	$31.36M	$11.39B	N/A	1,063	Positive News
COSM Cosmos Health	1.9131 of 5 stars	$0.19 -7.6%	N/A	-73.7%	$11.47M	$65.27M	N/A	100	Earnings Report Analyst Revision
WGRX Wellgistics Health	0.3417 of 5 stars	$3.46 -1.7%	N/A	-92.7%	$8.69M	$23.34M	N/A	31	Gap Down High Trading Volume
HKPD Hong Kong Pharma Digital Technology	0.7857 of 5 stars	$0.40 -0.4%	N/A	-60.7%	$4.35M	$13.43M	N/A	19	Positive News Gap Down
RDGT Ridgetech	0.6442 of 5 stars	$0.82 -1.0%	N/A	-99.6%	$2.92M	$132.16M	N/A	980	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:YI) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

111 (YI) Competitors